Molecular Organization of the Organic Cation-Proton Exchanger, MATE1
Molecular Organization of the Organic Cation-Proton Exchanger, MATE1
批准号:
8730620
负责人:
GEOFFREY A CHANG
金额:
$47.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-30 至 2017-07-31
关键词:
Amino AcidsApicalBindingBinding SitesBiologicalCarrier ProteinsCationsChargeComputing MethodologiesCrystallizationDataDevelopmentDrug DesignDrug InteractionsDrug KineticsEpithelialEpithelial CellsEpitheliumFaceFamilyFamily memberGenerationsHandHepaticHomology ModelingHumanKidneyLengthLigand BindingLigandsLiverMapsMediatingMethodsModelingMolecularMolecular ProfilingMorbidity - disease rateOrganOrganic Cation TransporterPathway interactionsPeptidesPharmaceutical PreparationsPharmacodynamicsPhysiologicalPlayProcessProgram DevelopmentProtein FamilyProteinsProteomicsProtonsQuantitative Structure-Activity RelationshipRoleSeriesSiteSolutionsSourceStructureStructure-Activity RelationshipSubstrate InteractionSurfaceTestingToxinTransport ProcessWorkbaseclinically significantdatabase designdesigndrug developmentextracellularfamily structureinhibitor/antagonistluminal membranemembermolecular dynamicsmortalitynovelpharmacophorepredictive modelingpreemptprotein aminoacid sequenceprotein structureresearch studythree dimensional structure
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The liver and kidney excrete from the body a wide array of positively charged organic molecules of physiological, pharmacological and toxicological significance. Carrier-mediated secretion of these "organic cations" (OCs), particularly by the kidney, has a profound influence on the pharmacokinetics of these compounds and, importantly, OC secretion is the site of many clinically significant drug-drug interactions. The active and rate-limiting step in OC secretion involves the carrier-mediated exit of accumulated OCs across the luminal membrane of renal and hepatic epithelia. The molecular identify of this process involves the newly identified Multidrug And Toxin Extrusion proteins, MATE1 and MATE2-K. Although now clearly understood to play a significant role in OC secretion, virtually nothing is known about the molecular determinants of substrate interaction with these transporters. In this revised proposal, we take advantage of the recent solution of the x- ray structure of a prototypic member of the MATE family of transport protein (NorM). We have used the NorM structure to develop a homology model of human MATE1 and, in this proposal, we outline two sets experiments designed to develop a predictive model of drug interaction with MATE transporters. In Aim 1, we take a ligand-based approach to develop 3D-QSAR/pharmacophore models of substrate/inhibitor interaction with MATE1 and MATE2-K. These data will be interpreted in the context of parallel studies on the integrated activity of these transporters in epithelial models of renal secretion (which, in turn, will be interpreted in the context of studies on the differential distribution of these transporters in human kidney). Aim 2 will employ a target-based approach, using site-directed studies to probe the topology and surface accessibility of MATE1, thereby testing predictions arising from our homology model, and establishing a database designed to probe the functional structure of the protein as determined in a parallel effort to solve the x-ray structure of human MATE1. Aim 2 will also study the substrate translocation pathway of MATE1 in studies that apply (i) proteomic methods to identify peptides and amino acid residues that specifically interact with a photoactivatable probe of the OC/H+ exchanger; and (ii) apply computational methods (steered molecular dynamics) to identify amino acid residues that influence substrate translocation. These studies will play a critical role in establishing models that accurately predict and, ideally, preempt unwanted interactions of cationic drugs in both the kidney and liver.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1038/s41598-017-18146-8
发表时间:
2017-12-21
期刊:
Scientific reports
影响因子:
4.6
作者:
[Doshi R, McGrath AP, Piñeros M, Szewczyk P, Garza DM, Kochian LV, Chang G]
通讯作者:
Chang G
Biosynthesis of marine terpenoid natural products
-
批准号:10737210
-
项目类别:
-
资助金额:$50.4万
-
财政年份:2023
-
负责人:GEOFFREY A CHANG
-
依托单位:
Synthetically-evolved and engineered Nanobodies selective for Cb isoforms of PKA
-
批准号:10525796
-
项目类别:
-
资助金额:$43.45万
-
财政年份:2022
-
负责人:GEOFFREY A CHANG
-
依托单位:
Nanobody inhibitors of proton-sensing G protein-coupled receptors
-
批准号:10216432
-
项目类别:
-
资助金额:$15.78万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
-
批准号:10380036
-
项目类别:
-
资助金额:$78.24万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
-
批准号:10184466
-
项目类别:
-
资助金额:$75.92万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
Development of low-cost, field-ready nanobodies against snake venom
-
批准号:10255596
-
项目类别:
-
资助金额:$25.59万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation
-
批准号:10594973
-
项目类别:
-
资助金额:$75.99万
-
财政年份:2021
-
负责人:GEOFFREY A CHANG
-
依托单位:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
-
批准号:9893680
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2019
-
负责人:GEOFFREY A CHANG
-
依托单位:
Down syndrome, early cataracts, eye diseases, and beta-amyloid conformers
-
批准号:10018872
-
项目类别:
-
资助金额:$19.7万
-
财政年份:2019
-
负责人:GEOFFREY A CHANG
-
依托单位:
Identity, mechanisms and early life impacts of transporter interfering compounds
-
批准号:10179393
-
项目类别:
-
资助金额:$55.86万
-
财政年份:2018
-
负责人:GEOFFREY A CHANG
-
依托单位:
Identity, mechanisms and early life impacts of transporter interfering compounds
-
批准号:10424481
-
项目类别:
-
资助金额:$53.94万
-
财政年份:2018
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure-based optimization of a novel pharmacological chaperone therapy for MPSIIIC
-
批准号:9343249
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2017
-
负责人:GEOFFREY A CHANG
-
依托单位:
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease
-
批准号:9262289
-
项目类别:
-
资助金额:$58.41万
-
财政年份:2014
-
负责人:GEOFFREY A CHANG
-
依托单位:
Targeting the mitochondrial pyruvate carrier to treat neurodegenerative disease
-
批准号:8843561
-
项目类别:
-
资助金额:$58.41万
-
财政年份:2014
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:8389520
-
项目类别:
-
资助金额:$17.47万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:8707456
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:9115590
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structure and function of ABC transporters to understand persistence of global ma
-
批准号:8550059
-
项目类别:
-
资助金额:$17.43万
-
财政年份:2012
-
负责人:GEOFFREY A CHANG
-
依托单位:
GEOFF CHANG PRT-CRYSTALLOGRAPHY OF INTEGRAL MEMBRANE PROTEINS
-
批准号:8362052
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2011
-
负责人:GEOFFREY A CHANG
-
依托单位:
Structural biology and high resolution studies of P-glycoprotein
-
批准号:8536320
-
项目类别:
-
资助金额:$28.47万
-
财政年份:2010
-
负责人:GEOFFREY A CHANG
-
依托单位:
国内基金
海外基金
FGF8通过Ras/MEK/ERK信号通路调控apical ES结构影响精子生成的机制研究
-
批准号:81801519
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:于岚
-
依托单位: